Craig-Hallum Maintains Buy on Cellebrite DI, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Jeff Van Rhee maintains a Buy rating on Cellebrite DI (NASDAQ:CLBT) and raises the price target from $14 to $16.
April 01, 2024 | 6:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellebrite DI's Buy rating is maintained by Craig-Hallum, with the price target increased from $14 to $16.
The maintenance of a Buy rating combined with an increased price target typically signals a positive outlook on the stock from the analyst's perspective. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100